The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M mutation leads to resistance to most clinically available EGFR TKIs. Third-generation EGFR TKIs against the T790M mutation have been in active clinical development. These agents include osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775.Osimertinib and rociletinib have shown clinical efficacy in phase I/II trials in patients who had acquired resistance to first- or second-generation TKIs. Osimertinib (AZD9291, TAGRISSO) was recently approved by FDA for metastatic EGFR T790M mutation-positive NSCLC. HM61713, ASP8237, EGF816, and PF-06747775 are still in early clinical development. This article reviews the emerging data regarding third-generation agents against EGFR T790M mutation in the treatment of patients with advanced NSCLC. Read more…..
- Third-generation inhibitors targeting EGFR T790M mutation in advanced NSCLC
- Osimertinib Given as First-Line Treatment May Alter Biology of EGFR-Mutated NSCLC
- Osimertinib approved in EU as first-in-class treatment for NSCLC
- Osimertinib Given as First-line Treatment May Alter Biology of EGFR-Mutated Non-Small-Cell Lung Cancer
GLOBAL MARKETING PARTNER
Beacon Medicare Limited 9/B/2,Toyenbee Circular Road, Motijheel,Dhaka-1223, Bangladesh Phone: +880-2-57165371/79 Fax: +880 2-8870109 Web: beaconmedicare.com.bd